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Central nervous system 
Etomoxir 
Neuromyelitis optica spectrum disorder 
Metabolic 
A B S T R A C T   
Astrocyte pathology is a feature of neuromyelitis optica spectrum disorder (NMOSD) pathology. Recently 
mitochondrial dysfunction and metabolic changes were suggested to play a role in NMOSD. To elucidate the role 
of mitochondrial dysfunction, astrocyte pathology was induced in C57BL/6 J female mice by intracerebral in-
jection of aquaporin-4-immunoglobulin G from an NMOSD patient, together with complement. Etomoxir has 
been shown to cause mitochondrial dysfunction. Etomoxir was delivered to the central nervous system and 
resulted in decreased astrocyte pathology. The ameliorating effect was associated with increases in different 
acylcarnitines and amino acids. This suggests that mitochondria may be a therapeutic target in NMOSD.   
1. Introduction 
The pathological hallmarks of neuromyelitis optica spectrum disor-
der (NMOSD) include astrocyte pathology, caused by disease-specific 
autoantibody against the astrocyte water channel aquaporin-4 (AQP4) 
in the central nervous system (CNS) (Bennett and Owens, 2017; Wein-
shenker and Wingerchuk, 2017). Recently mitochondrial dysfunction 
has been suggested to play a role in disease progression, disability level 
and cognitive impairment (Foolad et al., 2020). Mitochondrial DNA in 
cerebrospinal fluid was elevated in the acute phase of NMOSD (Yama-
shita et al., 2018) and associated to disease severity (Peng et al., 2020). 
Additionally, an altered energy metabolism has been associated to dis-
ease (Jurynczyk et al., 2017; Kim et al., 2017). This points to a role for 
mitochondria in disease development and progression. 
The drug etomoxir results in altered metabolism through interaction 
with mitochondria at different levels. It blocks beta-oxidation by 
inhibiting the activity of carnitine palmitoyl transferase-1 (CPT-1), an 
enzyme involved in transport of lipids across the mitochondrial mem-
brane (Bonnefont et al., 2004; Houten and Wanders, 2010), and it in-
hibits oxidative phosphorylation through actions on complex I in the 
electron transport chain (O'Connor et al., 2018; Yao et al., 2018). These 
actions have been shown to induce mitochondrial dysfunction (Vickers 
et al., 2006). We therefore utilized etomoxir to examine how alterations 




Young adult (8–12 weeks) female C57Bl/6J mice (Taconic, Lille 
Skensved, Denmark) were housed in the Biomedical Laboratory, Uni-
versity of Southern Denmark. Experiments were conducted in accor-
dance with the National Ethical Committee, Animal Experiments 
Inspectorate under the Danish Ministry of Food, Agriculture and Fish-
eries, and The Danish Veterinary and Food Administration (approval 
number 2020-15-0201-00652). Use of human material (NMO-IgG) was 
approved by the Committee on Biomedical Research Ethics for the Re-
gion of Southern Denmark (ref. no. S20080142). 
Abbreviations: AQP4, aquaporin 4; C, complement; CPT-1, carnitine palmitoyl transferase-1; NMO-IgG, human IgG from neuromyelitis optica spectrum disorder 
patients positive for AQP4-IgG; Normal-IgG, human IgG from healthy donors. 
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2.2. Induction of astrocyte pathology and treatment 
Mice were anesthetized by isoflurane inhalation or subcutaneous 
injection of a mixture of 0.79 μg Fentanylcitrate, 25 μg Fluanisone, 1,25 
μg methylparahydroxybenzoate and 12.5 μg midazolam in water / 10 g 
body weight. We observed no differences or grouping in the calculated 
loss of AQP4 or GFAP with regards to anaesthesia protocol, therefore we 
conclude that anaesthesia protocols did not affect outcome. Stereotactic 
coordinates were relative to bregma: 2 mm lateral, 0.2 mm anterior and 
3.5 mm ventral. A 30-gauge needle attached to a 50 μl Hamilton syringe 
was inserted and a total of 6 μl was infused at 1 μl/min (150 μg NMO-IgG 
(patient-derived) or normal-IgG (healthy donor) + 144 μg complement 
(C) (healthy donors) (Asgari et al., 2013), with or without etomoxir (0.5 
μg, Merck, Sigma-Aldrich, Søborg, Denmark)). Two days later mice 
received a total volume of 10 μl containing etomoxir (0.5 μg, Merck, 
Sigma-Aldrich) or vehicle (HBSS) intrathecally via cisterna magna. Mice 
were sacrificed at day 4. Brains were dissected out and processed as 
previously described (Asgari et al., 2013). 
2.3. Immunostaining 
Brains were cut on a cryostat into serial coronal sections of 12 μm 
thickness spanning the lesion and stained with primary antibodies 
against AQP4 (Alomone Labs Ltd. Jerusalem, Israel, 8 μg/ml), glial 
fibrillary acidic protein (GFAP) (DAKO, Denmark, 2.9 μg/ml). The sec-
tions were incubated with biotinylated goat anti-rabbit IgG (Abcam, 2,5 
μg/ml), followed by incubation with streptavidin-horseradish peroxi-
dase (Cytiva, Brønshøj, Denmark) and developed with 3,3′-dia-
minobenzidine (Merck). 
2.4. Quantification of lesions 
Images were acquired using an Olympus BX51 microscope with an 
Olympus DP73 camera (Olympus, Ballerup, Denmark). Loss of AQP4 
and GFAP staining was quantified as percentage of the ipsilateral 
hemisphere. The area of loss was measured and then divided by the area 
of the ipsilateral hemisphere. Measurements were done using the free 
software Fiji, ImageJ. Fold change was then attained by calculating the 
average value for control and then all measured values both for the 
control group and for the etomoxir group were divided by the control 
group average. ((measured values)/(average value calculated from 
control group) = fold change values). 
2.5. Measurement of acylcarnitines and animo acids 
Approximately 100 mg brain tissue including the lesion were 
dissected out and collected in 1 ml radioimmunoprecipitation assay 
(RIPA) lysis and extraction buffer. Samples were homogenized by son-
ication then spun down at 14000 g for 15 min. 
The metabolite extraction and butanol derivatization are based on a 
previously described method (Rashed et al., 1995). All samples were 
measured in triplicates. Briefly, 5 μL of each sample was added to a well 
of a 96-well filter plate with semipermeable membrane (Multiscreen- 
HV, 0.45 μm, Merck, USA). The samples were extracted with 120 μL of 
methanol containing known concentrations of deuterated labeled amino 
acid and acylcarnitine standards (Cambridge Isotope Laboratory, UK). 
The labeled standards had the following concentrations: 15N, 2-13C- 
Glycine, 12.5 μM; [2H4]-Alanine, 2.5 μM; [2H8]-Valine, 2.5 μM; [2H3]- 
Leucine, 2.5 μM; [2H3]-Methionine, 2.5 μM; [2H5]-Phenylalanine, 2.5 
μM; [2H4]-Tyrosine, 2.5 μM; [2H3]-Aspartate, 2.5 μM; [2H3]-Glutamate, 
2.5 μM; [2H2]-Ornithine-2HCl, 2.5 μM; [2H2]-Citrulline, 2.5 μM; [2H4]; 
5-13C-Arginine, 2.5 μM; [2H9]-Carnitine, 0.76 μM; [2H3]-Acetylcarni-
tine, 0.19 μM; [2H3]-Propionylcarnitine, 0.04 μM; [2H3]-Butyr-
ylcarnitine, 0.04 μM; [2H9]-Isovalerylcarnitine, 0.04 μM; [2H3]- 
Octanoylcarnitine, 0.04 μM; [2H9]-Myristoylcarnitine, 0.04 μM; [2H3]- 
Palmitoylcarnitine, 0.08 μM. The plates were covered and shaken at 
room temperature for 45 min on a horizontal shaker. The samples were 
then filtered into a 96-well polypropylene microplate by centrifugation 
(3000 rpm for 5 min) and evaporated under air at 55 ◦C until dry. For the 
butanol derivatization, 60 μL of n-butanol in HCl was added to each 
sample well and the plate incubated at 65 ◦C for 20 min. The samples 
were evaporated again and reconstituted in 100 μL of acetonitrile/H2O 
(80:20). 
The concentrations of amino acids and acylcarnitines were measured 
using flow-injection analysis coupled with tandem mass spectrometry 
(FIA-MS/MS). The FIA-MS/MS analysis was carried out on a Quattro 
Micro triple-quadrupole tandem mass spectrometer (Waters, UK) 
equipped with a liquid chromatography pump and autosampler (Alli-
ance High Throughput HPLC, Waters, UK) operating in positive ioni-
zation mode. Acylcarnitines and free carnitine were analyzed by the 
precursor-ion scan of m/z 85; amino acids were analyzed by two scan 
functions, the neutral amino acids with neutral loss of m/z 102 and basic 
amino acids with neutral loss of m/z 119. Lastly, glycine, arginine, and 
argininosuccinic acid and their corresponding internal standards were 
analyzed in multiple reaction monitoring (MRM) mode. 
2.6. Statistical analysis 
Statistical analysis was done using GraphPad Prism version 9 
(GraphPad Software Inc., San Diego, CA, USA). Data were examined for 
outliers using the ROUT test (Q = 1) and identified outliers were 
excluded from further testing. Significant differences were calculated 
using multiple or single Mann–Whitney test, assuming a nonparametric 
distribution. Data are presented as mean ± SEM. Values of p < 0.05 are 
considered statistically significant. 
3. Results 
To ascertain metabolic effect in our model of astrocyte pathology, 
etomoxir was co-injected intrastriatally with normal-IgG + C or NMO- 
IgG + C to C57BL/6 mice on day zero and intrathecally injected on day 
two. Mice were sacrificed four days post intra-striatal injection and 
lesion and surrounding tissue were analyzed by FIA-MS/MS. Surpris-
ingly, administration of etomoxir resulted in increased levels of short 
(C3DC, C5-OH), medium (C8:1, C8DC, C10DC, C12DC), long (C16:1- 
OH) and very long (C22, C26) chain acylcarnitines (Fig. 1A) and some 
amino acids (glutamine, lysine and valine) (Fig. 1B). However, levels of 
tyrosine were decreased (Fig. 1B). We next examined if the changes 
induced by etomoxir were associated to changes in development of 
astrocyte pathology. We have previously shown that injection of normal- 
IgG + C and NMO-IgG alone did not cause loss of AQP4 or GFAP (Asgari 
et al., 2013; Khorooshi et al., 2013; Mørch et al., 2018; Wlodarczyk 
et al., 2020). NMO-IgG + C induced lesions of astrocyte pathology, 
identified by loss of AQP4 and GFAP (Fig. 2A, the area with pathology is 
outlined) as well as deposition of complement and human IgG (not 
shown). Unexpectedly, administration of etomoxir directly in the CNS 
visibly reduced astrocyte pathology (loss of AQP4 and GFAP) (Fig. 2B), 
and significantly reduced the quantification of both loss of AQP4 
(Fig. 2C) and GFAP (Fig. 2D). Histological analysis of microglia using 
Iba1 staining showed no visual change in activation by etomoxir (supp. 
Fig. S1). 
4. Discussion 
This study examined the effect of mitochondrial dysfunction in the 
CNS on astrocyte pathology. Local treatment with etomoxir in the CNS 
was associated with increased acylcarnitines and amino acids and sur-
prisingly, reduced astrocyte pathology. 
As far as we are aware, this is the first study of the role of etomoxir 
directly in the CNS as well as being the first study on the role of mito-
chondria in NMO-IgG induced astrocyte pathology. Etomoxir has pre-
viously been shown to ameliorate CNS pathology in experimental 
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autoimmune encephalomyelitis (Shriver and Manchester, 2011; 
Mørkholt et al., 2018). However, the treatment was administered 
peripherally, and it cannot be excluded that the ameliorating effect of 
etomoxir was due to effects on the peripheral lymphoid compartment - 
etomoxir treatment of T cell cultures resulted in reduced interferon- 
gamma levels and increased apoptosis (Shriver and Manchester, 
2011). In the current study we utilized a model that mimics the astrocyte 
pathology seen in NMOSD. NMO-IgG + C is administered directly to the 
CNS with minimal involvement of the peripheral immune compartment. 
This would support that the effect of etomoxir which we observed was a 
direct CNS effect. 
Mitochondrial dysfunction has been implicated in motor and 
cognitive symptoms of NMOSD (Foolad et al., 2020), and CSF correlates 
were associated to development of pathology (Yamashita et al., 2018; 
Peng et al., 2020). Unexpectedly, we observed here that changes in 
mitochondrial function caused by etomoxir resulted in amelioration of 
astrocyte pathology. Astrocytes themselves may have been directly 
affected by etomoxir. Although astrocytes with dysfunctional mito-
chondria survive and do not cause glial pathology (Supplie et al., 2017), 
functional mitochondrial electron transport chain and oxidative phos-
phorylation machinery in astrocytes were required for neuroprotection 
in a model for ischemic stroke (Fiebig et al., 2019). In the current study 
we found no obvious evidence of astrocyte reactivity having been 
affected by etomoxir. Another question is whether pathology and its 
protection should necessarily reflect mitochondrial dysfunction in as-
trocytes. We have previously shown that microglia play a central role in 
development of NMOSD-like pathology in our model, as depletion of 
microglia resulted in reduced astrocyte pathology (Wlodarczyk et al., 
2020). Anti-inflammatory microglia/macrophages rely on oxidative 
phosphorylation and at times fatty acid oxidation while pro- 
inflammatory microglia and macrophages undergo a switch towards 
glycolysis to meet cellular demands and cell survival (Harry et al., 
2020). Furthermore, etomoxir has been shown to induce mitochondrial 
dysfunction (Vickers et al., 2006) and mitochondrial status has been 
linked to functional outputs eg phagocytosis in macrophages (Chen 
et al., 2018; Belchamber et al., 2019) and microglia (Rubio-Araiz et al., 
2018). Interfering with this shift should reverse inflammation. This 
could account for the effect of Etomoxir in our study. However, a his-
tological examination of microglia/macrophages reactivity using Iba1 
staining showed no immediate differences in activation such as we 
previously observed in IFNAR1 KO mice (Khorooshi et al., 2013). In the 
current study, we have demonstrated “proof-of-concept” and we iden-
tified a role for mitochondrial function in NMOSD. We report amelio-
ration of NMOSD-like pathology by etomoxir; however, further in-depth 
studies are needed to clarify dose-response as well as the precise 
mechanism. 
Fig. 1. Etomoxir affects acylcarnitines in the CNS parenchyma. 
C57BL/6 J female mice were injected with Normal-IgG + C or NMO-IgG + C to striatum. The mice were treated with vehicle or etomoxir on day 0 (intracerebral) and 
again on day two (intrathecal). Mice were sacrificed on day four. A tissue block of approximately 100 mg containing the lesioned area was microdissected out and 
acylcarnitines and amino acids were measured using flow-injection analysis coupled with tandem mass spectrometry in both the vehicle and etomoxir group (fold 
change to vehicle, n = 5). A: Acylcarnitines with significant changes after treatment with etomoxir in either Normal-IgG + C or NMO-IgG + C group. B: Significant 
changes in amino acids after etomoxir treatment in either Normal-IgG + C or NMO-IgG + C group. 
Outliers were identified using the ROUT test, Q = 1, then removed. Nonparametric Mann-Whitney U test was used for statistical analysis. *P ≤ 0.05 and **P ≤ 0.01. 
Results are presented as mean ± SEM. 
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Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.jneuroim.2021.577657. 
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and Freyr Jóhannsson (Department of Genetics and Molecular Medicine, 
Landspitali, Iceland) for preforming FIA-MS/MS and analyzing those 
data. 
References 
Asgari, N., Khorooshi, R., Lillevang, S.T., Owens, T., 2013. Complement-dependent 
pathogenicity of brain-specific antibodies in cerebrospinal fluid. J. Neuroimmunol. 
254, 76–82. https://doi.org/10.1016/j.jneuroim.2012.09.010. 
Belchamber, K.B.R., Singh, R., Batista, C.M., Whyte, M.K., Dockrell, D.H., Kilty, I., et al., 
2019. Defective bacterial phagocytosis is associated with dysfunctional 
mitochondria in COPD macrophages. Eur. Respir. J. 54. https://doi.org/10.1183/ 
13993003.02244-2018. 
Bennett, J.L., Owens, G.P., 2017. Neuromyelitis optica: deciphering a complex immune- 
mediated Astrocytopathy. J. Neuroophthalmol. 37, 291–299. https://doi.org/ 
10.1097/WNO.0000000000000508. 
Bonnefont, J.-P., Djouadi, F., Prip-Buus, C., Gobin, S., Munnich, A., Bastin, J., 2004. 
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical 
aspects. Mol. Asp. Med. 25, 495–520. https://doi.org/10.1016/j.mam.2004.06.004. 
Chen, Q., Wang, N., Zhu, M., Lu, J., Zhong, H., Xue, X., et al., 2018. TiO2 nanoparticles 
cause mitochondrial dysfunction, activate inflammatory responses, and attenuate 
phagocytosis in macrophages: a proteomic and metabolomic insight. Redox Biol. 15, 
266–276. https://doi.org/10.1016/j.redox.2017.12.011. 
Fiebig, C., Keiner, S., Ebert, B., Schäffner, I., Jagasia, R., Lie, D.C., et al., 2019. 
Mitochondrial dysfunction in astrocytes impairs the generation of reactive astrocytes 
and enhances neuronal cell death in the cortex upon Photothrombotic lesion. Front. 
Mol. Neurosci. 12, 40. https://doi.org/10.3389/fnmol.2019.00040. 
Foolad, F., Khodagholi, F., Nabavi, S.M., Javan, M., 2020. Changes in mitochondrial 
function in patients with neuromyelitis optica; correlations with motor and cognitive 
disabilities. PLoS One 15, e0230691. https://doi.org/10.1371/journal. 
pone.0230691. 
Harry, G.J., Childers, G., Giridharan, S., Hernandes, I.L., 2020. An association between 
mitochondria and microglia effector function: what do we think we know? 
Neuroimmunol. Neuroinflam. 7, 150–165. https://doi.org/10.20517/2347- 
8659.2020.07. 
Houten, S.M., Wanders, R.J.A., 2010. A general introduction to the biochemistry of 
mitochondrial fatty acid β-oxidation. J. Inherit. Metab. Dis. 33, 469–477. https:// 
doi.org/10.1007/s10545-010-9061-2. 
Jurynczyk, M., Probert, F., Yeo, T., Tackley, G., Claridge, T.D.W., Cavey, A., et al., 2017. 
Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, 
AQP4-antibody and MOG-antibody disease. Acta Neuropathol. Commun 5. https:// 
doi.org/10.1186/s40478-017-0495-8. 
Khorooshi, R., Wlodarczyk, A., Asgari, N., Owens, T., 2013. Neuromyelitis optica-like 
pathology is dependent on type I interferon response. Exp. Neurol. 247, 744–747. 
https://doi.org/10.1016/j.expneurol.2013.02.005. 
Kim, H.-H., Jeong, I.H., Hyun, J.-S., Kong, B.S., Kim, H.J., Park, S.J., 2017. Metabolomic 
profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by 
nuclear magnetic resonance. PLoS One 12. https://doi.org/10.1371/journal. 
pone.0181758. 
Fig. 2. Etomoxir attenuates AQP4-IgG + C induced 
astrocyte pathology. 
Astrocyte pathology was induced in C57BL/6 J fe-
male mice by injection of AQP4-IgG + C to striatum. 
The mice were treated with vehicle or etomoxir on 
day 0 (intracerebral) and again on day two (intra-
thecal). Mice were sacrificed on day four. (A, B): 
Overview of brain sections from vehicle- and 
etomoxir-treated mice stained for AQP4 and GFAP. 
The area with pathology is outlined. (C, D): Bar 
graphs show the normalized values of AQP4 and 
GFAP loss from vehicle (n = 9) and etomoxir treated 
(n = 6) group. 
Outliers were identified using the ROUT test, Q = 1, 
then removed. Nonparametric Mann-Whitney U test 
was used for statistical analysis. LV: lateral ventricle. 
Scale bars for A and B = 200 μm. *P ≤ 0.05. Results 
are presented as mean ± SEM.   
M.T. Morch et al.                                                                                                                                                                                                                               
Journal of Neuroimmunology 358 (2021) 577657
5
Mørch, M.T., Sørensen, S.F., Khorooshi, R., Asgari, N., Owens, T., 2018. Selective 
localization of IgG from cerebrospinal fluid to brain parenchyma. 
J. Neuroinflammation 15. https://doi.org/10.1186/s12974-018-1159-8. 
Mørkholt, A.S., Kastaniegaard, K., Trabjerg, M.S., Gopalasingam, G., Niganze, W., 
Larsen, A., et al., 2018. Identification of brain antigens recognized by autoantibodies 
in experimental autoimmune encephalomyelitis-induced animals treated with 
etomoxir or interferon-β. Sci. Rep. 8. https://doi.org/10.1038/s41598-018-25391-y. 
O’Connor, R.S., Guo, L., Ghassemi, S., Snyder, N.W., Worth, A.J., Weng, L., et al., 2018. 
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used 
concentrations. Sci. Rep. 8, 6289. https://doi.org/10.1038/s41598-018-24676-6. 
Peng, Y., Chen, J., Dai, Y., Jiang, Y., Qiu, W., Gu, Y., et al., 2020. NLRP3 level in 
cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: 
increased levels and association with disease severity. Mult. Scleros. Rel. Disord. 39, 
101888. https://doi.org/10.1016/j.msard.2019.101888. 
Rashed, M.S., Ozand, P.T., Bucknall, M.P., Little, D., 1995. Diagnosis of inborn errors of 
metabolism from blood spots by acylcarnitines and amino acids profiling using 
automated electrospray tandem mass spectrometry. Pediatr. Res. 38, 324–331. 
https://doi.org/10.1203/00006450-199509000-00009. 
Rubio-Araiz, A., Finucane, O.M., Keogh, S., Lynch, M.A., 2018. Anti-TLR2 antibody 
triggers oxidative phosphorylation in microglia and increases phagocytosis of 
β-amyloid. J. Neuroinflammation 15, 247. https://doi.org/10.1186/s12974-018- 
1281-7. 
Shriver, L.P., Manchester, M., 2011. Inhibition of fatty acid metabolism ameliorates 
disease activity in an animal model of multiple sclerosis. Sci. Rep. 1 https://doi.org/ 
10.1038/srep00079. 
Supplie, L.M., Düking, T., Campbell, G., Diaz, F., Moraes, C.T., Götz, M., et al., 2017. 
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